Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations (“eRapa”) and Use Biodexa plans ...

Expanded conditional approval allows drugs that are undergoing their final clinical trial assessment and are supported by ...

The Fast Track designation is supported by data from a phase 2 trial that evaluated eRapa in 30 adult patients with FAP.

Biodexa Announces Allowance of U.S. Patent Covering Oral Rapamycin Nanoparticle Preparations ("eRapa") and Use Biodexa plans to initiate a Phase 3 registrational study of eRapa in Familial ...

A newly published study in Genes & Diseases highlights the crucial role of the mammalian target of rapamycin (mTOR) pathway in the progression of diabetic nephropathy (DN) and explores its potential ...

A live webcast of the presentation will be available on the Events and Presentations section of Palvella's website at www.palvellatx.com. An archived replay of the webcast will be available for ...

One such drug is rapamycin, a pill that is typically prescribed to patients ahead of organ transplants "to bring the immune ...

Signaling via mammalian target of rapamycin (mTOR), which is known to control mRNA translation and influence synaptic plasticity, has been studied at the spinal level in neuropathic pain, but its role ...

Biodexa Pharmaceuticals (BDRX) announced that the U.S. Patent and Trademark Office allowed has U.S. patent application No. 17/391.495 titled ...

A newly published study in Genes & Diseases highlights the crucial role of the mammalian target of rapamycin (mTOR) pathway ...

Palvella Therapeutics is set to expand its 24-week Phase III SELVA trial to include subjects aged three to five years old for ...